Ikena Oncology (IKNA) Q3 2024 earnings summary

Executive summary

• Ikena Oncology is a clinical-stage targeted oncology company focused on therapies for cancer growth, spread, and resistance, with a primary focus on the RAS pathway program IK-595.

• In 2024, the company underwent two major restructurings, reducing its workforce by 35% in January and 53% in May, discontinuing discovery efforts and the IK-930 program to focus on IK-595 and explore strategic alternatives.

• The company is actively seeking strategic options, including potential transactions, but no definitive course of action has been approved.

Financial highlights

• Net loss for the three months ended September 30, 2024 was $10.2 million, a 41% improvement compared to a net loss of $17.3 million in the same quarter last year.

• Net loss for the nine months ended September 30, 2024 was $40.1 million, compared to $48.7 million for the same period in 2023.

• Research and development expenses decreased 53% year-over-year to $6.8 million for the quarter, and 42% to $26.3 million for the nine-month period, reflecting program prioritization and workforce reductions.

• General and administrative expenses declined 21% year-over-year to $4.8 million for the quarter and 3% to $16.1 million for the nine-month period.

• Cash, cash equivalents, and marketable securities totaled $138.0 million as of September 30, 2024.

• No revenue from product sales; all revenue in 2023 and 2024 was from a now-concluded collaboration with Bristol-Myers Squibb.

Outlook and guidance

• Cash, cash equivalents, and marketable securities are expected to fund operations for at least 12 months from the filing date.

• The company anticipates continued expenses related to strategic review and ongoing development of IK-595.

• Additional funding may be required if strategic alternatives are not realized or if development plans expand.